Kevin Majchszak
Adult Health · Belleville, MINPI 1134196645
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.
Across 178 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$545
- AstraZeneca$504
- AbbVie$474
- GSK$364
- Amgen$189
- Scynexis, Inc.$126
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,26596%
- Entertainment$1264%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 31 | $545 |
| AstraZeneca | 26 | $504 |
| AbbVie(2 entities) | 32 | $474 |
| GSK | 20 | $364 |
| Amgen | 8 | $189 |
| Scynexis, Inc. | 1 | $126 |
| Amarin Pharma, Inc. | 9 | $120 |
| Pfizer | 6 | $113 |
| Biohaven Pharmaceuticals, Inc. | 5 | $101 |
| Indivior Inc. | 6 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $85 |
| Sunovion Pharmaceuticals Inc. | 5 | $77 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| Neurocrine Biosciences, Inc. | 1 | $55 |
| Lilly USA, LLC | 3 | $47 |
| Molnlycke Health Care US, LLC | 1 | $46 |
| Lundbeck LLC | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 1 | $41 |
| Dexcom, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Novo Nordisk | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Vertex | 1 | $23 |
| Alkermes, Inc. | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Abbott | 1 | $21 |
| Mylan Specialty L.p. | 1 | $21 |
| Orexo US, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
How this compares
$3,392 in reported general payments places this provider in the 85th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 185 | $119,171 |
| OzempicSemaglutide | 54 | $57,207 |
| RexultiBrexpiprazole | 29 | $41,330 |
| EliquisApixaban | 41 | $25,437 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 188 | $23,028 |
| JardianceEmpagliflozin | 23 | $18,240 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,591 | $14,929 |
| FarxigaDapagliflozin Propanediol | 17 | $12,765 |
| LinzessLinaclotide | 19 | $11,554 |
| MyrbetriqMirabegron | 19 | $8,367 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 250 | $7,945 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,778 |
| Ventolin HfaAlbuterol Sulfate | 62 | $3,610 |
| Verapamil Er PmVerapamil Hcl | 14 | $3,456 |
| Diclofenac Sodium | 165 | $3,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $364 | $119,171185 claims |
| Novo NordiskOzempic | $27 | $57,20754 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $545 | $41,33029 claims |
| PfizerEliquis | $113 | $25,43741 claims |
| Boehringer IngelheimJardiance | $26 | $18,24023 claims |
| AstraZenecaFarxiga | $504 | $12,76517 claims |
| AbbVieLinzess | $474 | $11,55419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 527 adult health providers in Michigan.
Other adult health in Belleville
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
- Mary KaiserKalamazoo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.